These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22913904)

  • 1. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
    Hasnain M; Vieweg WV; Hollett B
    Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight considerations in psychotropic drug prescribing and switching.
    Hasnain M; Vieweg WV
    Postgrad Med; 2013 Sep; 125(5):117-29. PubMed ID: 24113670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
    Cernea S; Dima L; Correll CU; Manu P
    Drugs; 2020 Nov; 80(17):1763-1781. PubMed ID: 32930957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between antiepileptics and second-generation antipsychotics.
    de Leon J; Santoro V; D'Arrigo C; Spina E
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):311-34. PubMed ID: 22332980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight gain and antipsychotics: a drug safety review.
    Musil R; Obermeier M; Russ P; Hamerle M
    Expert Opin Drug Saf; 2015 Jan; 14(1):73-96. PubMed ID: 25400109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label second generation antipsychotics for impulse regulation disorders: a review.
    Scheltema Beduin A; de Haan L
    Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.
    Spina E; de Leon J
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):721-46. PubMed ID: 24494611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.
    Tschoner A; Engl J; Rettenbacher M; Edlinger M; Kaser S; Tatarczyk T; Effenberger M; Patsch JR; Fleischhacker WW; Ebenbichler CF
    Pharmacopsychiatry; 2009 Jan; 42(1):29-34. PubMed ID: 19153944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturalistic impact of second-generation antipsychotics on weight gain.
    Brixner DI; Said Q; Corey-Lisle PK; Tuomari AV; L'italien GJ; Stockdale W; Oderda GM
    Ann Pharmacother; 2006 Apr; 40(4):626-32. PubMed ID: 16569802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
    Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
    J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.